Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia

• Published in: Clinical lymphoma, myeloma and leukemia Vol. 20; no. 7; pp. e382 - e391
• Main Authors: Yang, Shiwei, Ma, Rongjun, Yuan, Xiaoli, Jiang, Li, Shi, Jie, Yang, Jing, Lei, Pingchong, Zang, Yuzhu, Chen, Xiangli, Zhang, Yin, Liu, Zhongwen, Guo, Jianmin, Zhang, Lin, Zhu, Xiaojian, Zhu, Zunmin
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.07.2020
• Subjects: APL; FLT3-ITD; High risk; Prognosis; Triple treatment; High risk; Prognosis; APL; FLT3-ITD; Triple treatment
• ISSN: 2152-2650; 2152-2669
• DOI: 10.1016/j.clml.2019.10.003

The purpose of this study was to explore the outcomes of all-trans-retinoic acid (ATRA) and arsenic trioxide (ATO) plus idarubicin (IDA) as a frontline treatment in adult patients with acute promyelocytic leukemia (APL). We analyzed the outcomes of ATRA and intravenous ATO plus IDA as a frontline induction therapy in 118 patients with APL with high-risk (HR) and standard-risk (SR) disease from January 2008 to December 2017. The medical records of 118 patients with APL (HR, n = 45; SR, n = 73) who received the frontline triple combination regimen at Henan Provincial People’s Hospital and Tongji Hospital were retrospectively reviewed. Consolidation therapy comprised 6 cycles of ATO and ATRA plus IDA, and IDA was administered in 1 to 4 cycles of consolidation therapy based on the comparable clinical efficacy compared with 6 cycles and fewer side effects to myocardium without subsequent maintenance therapy. Of 118 patients, there were 3 (2.5%) early deaths and 115 (97.5%) hematologic complete remissions; 102 (88.7%) of 115 patients achieved molecular complete remission following induction therapy, and all patients were polymerase chain reaction-negative for promyelocytic leukemia-retinoic acid receptor alpha after the first cycle of consolidation therapy. The 5-year overall survival (OS) and event-free survival (EFS) were 93.0% ± 2.9% and 92.4% ± 3.0%, respectively. Early death, hematologic complete remissions, molecular complete remissions, and toxicities were comparable between the HR and SR groups. The cumulative incidence of relapse in the HR group was 4.7% (n = 2), and the cumulative incidence of relapse in the SR group was 0. The OS and EFS of the SR and HR groups were comparable (92.3% ± 4.5% vs. 92.8% ± 4.0%; X2 = 0.263; P = .608; 92.3% ± 4.5% vs. 91.1% ± 4.2%, X2 = 0.917; P = .338). The total dosage of IDA was approximately 181 to 258 mg, and no patient experienced cardiotoxicity. OS and EFS were not influenced by fms-related tyrosine kinase 3 internal tandem duplication mutation status (P = .405 and P = .528, respectively). The triple combination of ATRA and ATO plus IDA as both an induction and consolidation therapy for the HR and SR groups attained excellent outcomes, and this regimen was effective, safe, and easy, without maintenance therapy. The triple combination treatment might be a preferred frontline therapy for patients with APL, especially for those with HR or the APL fms-related tyrosine kinase 3 internal tandem duplication mutation. To explore the safety and effectiveness of the triple combination of all-trans-retinoic acid and arsenic trioxide plus idarubicin for acute promyelocytic leukemia, we analyzed the outcomes of 118 patients with acute promyelocytic leukemia. The overall and event-free survival of the high- and standard-risk groups were comparable. The triple treatment might be a preferred frontline therapy for the high-risk group or the fms-related tyrosine kinase 3 internal tandem duplication-positive group.